Intraperitoneal Infusion of Mesenchymal Stem-Stromal Cells Prevents Experimental Autoimmune Uveitis in MiceReport as inadecuate




Intraperitoneal Infusion of Mesenchymal Stem-Stromal Cells Prevents Experimental Autoimmune Uveitis in Mice - Download this document for free, or read online. Document in PDF available to download.

Mediators of Inflammation - Volume 2014 2014, Article ID 624640, 9 pages -

Research Article

Department of Ophthalmology, Seoul National University Hospital, Seoul 110-744, Republic of Korea

Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul National University Hospital Biomedical Research Institute, Seoul 110-744, Republic of Korea

Department of Ophthalmology, Seoul National University Boramae Medical Center, Seoul 156-707, Republic of Korea

Department of Ophthalmology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Republic of Korea

Received 6 March 2014; Revised 23 June 2014; Accepted 25 June 2014; Published 17 July 2014

Academic Editor: Francisco J. Ascaso

Copyright © 2014 Joo Youn Oh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Autoimmune uveitis is one of the leading causes of blindness. We here investigated whether intraperitoneal administration of human mesenchymal stem-stromal cells hMSCs might prevent development of experimental autoimmune uveitis EAU in mice. Time course study showed that the number of IFN-γ- or IL-17-expressing CD4

T cells was increased in draining lymph nodes DLNs on the postimmunization day 7 and decreased thereafter. The retinal structure was severely disrupted on day 21. An intraperitoneal injection of hMSCs at the time of immunization protected the retina from damage and suppressed the levels of proinflammatory cytokines in the eye. Analysis of DLNs on day 7 showed that hMSCs decreased the number of Th1 and Th17 cells. The hMSCs did not reduce the levels of IL-1β, IL-6, IL-12, and IL-23 which are the cytokines that drive Th1-Th17 differentiation. Also, hMSCs did not induce CD4

CD25

Foxp3

cells. However, hMSCs increased the level of an immunoregulatory cytokine IL-10 and the population of IL-10-expressing B220

CD19

cells. Together, data demonstrate that hMSCs attenuate EAU by suppressing Th1-Th17 cells and induce IL-10-expressing B220

CD19

cells. Our results support suggestions that hMSCs may offer a therapy for autoimmune diseases mediated by Th1-Th17 responses.





Author: Joo Youn Oh, Tae Wan Kim, Hyun Jeong Jeong, Hyun Ju Lee, Jin Suk Ryu, Won Ryang Wee, Jang Won Heo, and Mee Kum Kim

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents